Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …

Biotechnology

US, Cambridge [HQ]

Overview
Fin. Reports
Financials
Leadership & Strategy
Government, Law & Regulation
Employees
More

Lobbying · US Senate · Influence

Lobbying Analysis

Lobbying · US Senate · Influence

Here you'll find all expenses made over the past 12M of Intellia Therapeutics, Inc. to fulfill lobbying activities in the United States of America.

Intellia Therapeutics, Inc. has no lobbying expenses in our database.

FY	Quarter	Lobby Expense [in mil. $]	Filing	Report Time
No data